The Wild laboratory is located at the University Hospital of Zurich. The research program is devoted to the identification of clinically significant biomarkers for cancer and their implications for prognosis, therapy response, and classification of the disease and other fields. The laboratory is well equipped with next-generation sequencing platforms (Ion Torrent Proton, Ion Torrent PGM, Ion Torrent S5, Illumina MiSeq), real-time cell viability assays, a Q Exactive HF MS system (Thermo Fisher Scientific), fluorescence in situ hybridization (FISH) devices, and an Idylla Biocartis system.
Peter Wild, MD, is a senior consultant at Institute of Pathology and Molecular Pathology, University Hospital Zurich. He holds an academic rank of Professor of Systems Pathology, University of Zurich. His research focuses on molecular genetics of solid tumors. He has successfully established NGS technologies for diagnostic molecular pathology, and oranizes the Molecular Tumorboard Zurich (MTBZ). He completed his Pathology residency from the University of Regensburg, Hamburg-Eppendorf and Zurich in 2008. He has completed a postdoctoral training in Medical Biometrics at the University of Heidelberg, Germany. For a two year postdoctoral training in cell biology, he joined the lab of Willy Krek at ETH Zurich. In April 2010 he also received his Venia Legendi in Pathology from the University of Zurich. He receives funding for research from the European Commission (H2020, PrECISE), Oncosuisse and the Swiss National Science Foundation. He has been honored with various awards during his training and career, including the Rudolf-Virchow-Prize of the German Society of Pathology in 2013. Dr. Wild has co-authored more than 155 articles in peer-reviewed journals.
Dr. med. Peter Wild
für Pathologie und Molekularpathologie
Tel +41 44
255 39 email@example.com
Zurich / Switzerland